The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor
Yucai Wang(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Asher Chanan‐Khan(WinnMed), Min Shi(Mayo Clinic in Arizona), Amie Fonder, Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic in Arizona), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Susan L. Slager(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Wei Ding(Ministry of Education of the People's Republic of China), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Suzanne R. Hayman, Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Michael S. Bold(Mayo Clinic in Arizona)
Cited by 35
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727